Goldman Sachs Keeps Buy Rating on Vertex Pharmaceuticals

Goldman Sachs analyst Salveen Richter has maintained a buy rating for Vertex Pharmaceuticals (VRTX.US) and stuck to its target price of $653. This decision was based on the analyst's research and assessment of the company's prospects.

Richter's success rate over the past year is 50.4%, with an average return of 12.3%. TipRanks provides data analysis from financial analysts, calculating their success rates and total average returns based on virtual portfolios established according to their preliminary ratings.